“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...
Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host...
Welcome to a special epsiode of Few & Far Between. Our guest this week is oncologist Dr. Alex Adjei, Scientific Advisory Board Member at...